FMP

FMP

Enter

ALIM - Alimera Sciences, In...

photo-url-https://images.financialmodelingprep.com/symbol/ALIM.png

Alimera Sciences, Inc.

ALIM

NASDAQ

Inactive Equity

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

5.54 USD

-0.01 (-0.181%)

About

ceo

Mr. Richard S. Eiswirth Jr.

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

exchange

NASDAQ

Description

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

CIK

0001267602

ISIN

US0162592028

CUSIP

016259202

Address

6310 Town Square

Phone

678 990 5740

Country

US

Employee

154

IPO Date

Nov 4, 2019

Key Executives

Name

Title

Pay

Year Born

Mr. Jason Werner

Chief Operating Officer

225.66k

1978

Dr. David Dyer M.D.

Chief Retina Specialist

0

N/A

Dr. Philip Ashman Ph.D.

President of International Operations

516.98k

1965

Christopher S. Visick

Vice President, General Counsel & Secret...

0

N/A

Mr. Todd Michael Wood

President of U.S. Operations

0

1969

Mr. Elliot Maltz CPA

Chief Financial Officer & Treasurer

0

1985

Mr. Richard S. Eiswirth Jr.

Chief Executive Officer & Director

949.27k

1968

Mr. David R. Holland

Co-Founder, Chief Marketing Officer and ...

413.5k

1964

As of December 31, 2024, the total employee count stands at 154, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep